

**MATERIAL CHANGE REPORT  
FORM 51-102F3**

**Item 1. Name and Address**

Jolt Health Inc. (formerly Love Pharma Inc.) (the “Company”)  
1780-355 Burrard Street  
Vancouver, BC  
V6C 2C8

**Item 2. Date of Material Change**

May 25, 2023

**Item 3. News Release**

The news release describing the material change was disseminated on May 25, 2023 through GlobeNewswire and filed on SEDAR.

**Item 4. Summary of Material Change**

The Company announced that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022, the Issuer issued a total of 13,765,763 common shares, at \$0.015 per common share in satisfaction of the aggregate interest payment owed by the Issuer of \$195,000 to a Debenture holder. In addition, pursuant to Promissory Notes dated January 23, 2020 and extended to December 31, 2023, the Issuer issued a total of 6,116,913 common shares at \$0.15 per common share in satisfaction of the aggregate per annum interest rate of 5% owing on the Promissory Notes.

**Item 5. Full Description of Material Change**

**5.1 *Full Description of Material Change***

The Company announced that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022, the Issuer issued a total of 13,765,763 common shares, at \$0.015 per common share in satisfaction of the aggregate interest payment owed by the Issuer of \$195,000 to a Debenture holder. In addition, pursuant to Promissory Notes dated January 23, 2020 and extended to December 31, 2023, the Issuer issued a total of 6,116,913 common shares at \$0.15 per common share in satisfaction of the aggregate per annum interest rate of 5% owing on the Promissory Notes.

The common shares are being issued to arms-length parties, and are subject to a four month hold period. The shares for debt settlement is subject to the approval of the Canadian Securities Exchange.

**5.2 *Disclosure for Restructuring Transactions***

Not applicable.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

No information has been omitted in respect of this material change.

**Item 8. Executive Officer**

The following executive officer of the Company is knowledgeable about the material change disclosed in this report and may be contacted as follows:

Zach Stadnyk, President  
Telephone: 647 980-7541

**Item 9. Date of Report**

May 26, 2023.